Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QRX006
- Development stage
- Preclinical
- Lead developer
- Quoin Pharmaceuticals
01
Overview
QRX006 is a preclinical topical drug candidate being developed by Quoin Pharmaceuticals for an undisclosed rare dermatologic disease. Public disclosures describe it only as a therapy for rare skin disease, without specifying the molecular target, active ingredient, formulation, or precise indication, but it is part of Quoin’s portfolio of small‑molecule, topical products for orphan skin conditions such as Netherton syndrome and epidermolysis bullosa.[1][2][4][5]
Beyond the preview
Go deeper on QRX006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QRX006.